Because DUB3 has been demonstrated to drive chemoresistance in colorectal cancer and ovarian cancer via stabilizing NRF2 and MCL1 [31, 36], we explored whether DUB3 affects the response of HCC cells to the commonly used chemotherapeutic drugs for HCC treatment. The gene discussed is USP17L2; the disease is hepatocellular carcinoma.